RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of high-dose thiotepa plus peripheral stem cell transplantation in treating patients with refractory solid tumors.

Condition	Treatment or Intervention	Phase
Testicular Cancer Brain Tumor Eye Cancer	Procedure: chemotherapy  Procedure: biological response modifier therapy  Procedure: autologous bone marrow transplantation  Procedure: bone marrow transplantation  Procedure: colony-stimulating factor therapy  Procedure: peripheral blood stem cell transplantation  Procedure: cytokine therapy  Drug: bone marrow ablation with stem cell support  Drug: filgrastim  Drug: thiotepa	Phase II

Further Study Details: 

OBJECTIVES: I. Evaluate the efficacy and toxicity of sequential cycles of high dose thiotepa with stem cell rescue and filgrastim in patients with malignancies refractory to conventional chemotherapy or for whom conventional therapy is not available. II. Evaluate the effectiveness of autologous stem cells in restoring hematopoiesis following high dose thiotepa.

PROTOCOL OUTLINE: Patients are stratified by type of tumor (neuroectodermal CNS tumor vs non-neuroectodermal CNS tumor vs non-CNS small round blue cell tumor vs other non-CNS tumor). Autologous stem cells are obtained prior to the administration of thiotepa. Patients who do not have peripheral blood stem cells available may undergo a bone marrow harvest instead. Thiotepa is administered as a 3 hour infusion daily for 3 consecutive days. Stem cells are reinfused approximately 72 hours following the completion of thiotepa. Filgrastim is administered the day following reinfusion of stem cells and continues until there is sufficient hematopoietic recovery. The second course of thiotepa is administered 4 weeks following the first course in patients who have responding or stable disease, adequate stem cells, and no unacceptable toxicity. Patients receive a maximum of 2 courses.

PROJECTED ACCRUAL: Approximately 36 patients will be accrued for this study over 2 years.

Criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

Malignant solid tumors

Must have failed conventional treatment or for whom conventional therapy is not available

Measurable disease by MRI or CT scan

• Intraocular retinoblastomas may be measured by direct visualization
• Germ cell tumors may be measured by tumor markers

No known bone marrow involvement

--Prior/Concurrent Therapy--

Biologic therapy: Prior bone marrow or peripheral blood stem cell rescue allowed

Chemotherapy:

• At least 4 weeks since prior chemotherapy if absolute neutrophil count is less than 1,000/mm3 or platelet count is less than 75,000/mm3, and recovered (i.e. adequate stem cells collected to predict hematopoietic recovery)
• No concurrent chemotherapy except for dexamethasone for antiedema effects

Endocrine therapy: No concurrent use of corticosteroids used solely as antiemetics

Radiotherapy:

• At least 4 weeks since radiotherapy if absolute neutrophil count is less than 1,000/mm3 or platelet count is less than 75,000/mm3, and recovered (i.e. adequate stem cells collected to predict hematopoietic recovery)
• No concurrent radiotherapy

Surgery: Not specified

--Patient Characteristics--

Age: Any age

Performance status:

• Lansky 60-100% for patients 16 and under
• Karnofsky 60-100% for patients over 16

Life expectancy: At least 8 weeks

Hematopoietic:

• Absolute neutrophil count at least 1,000/mm3
• Platelet count at least 75,000/mm3
• If parameters not met, must have adequate stem cell yield

Hepatic:

• Bilirubin no greater than 1.5 times the upper limit of normal (ULN)
• SGOT and SGPT no greater than 2.5 times the ULN (unless liver involvement by tumor)

Renal:

• Creatinine within normal limits OR
• Creatinine clearance at least 70 mL/min

Cardiovascular:

• Fractional shortening greater than 28% on echocardiogram OR
• Ejection fraction at least 55% on RNCA prior to first cycle of thiotepa

Pulmonary: DLCO greater than 55% of predicted (only required if there is clinical evidence of pulmonary dysfunction)

Other:

• Not pregnant or nursing
• Fertile patients must use effective contraception

New York
      Memorial Sloan-Kettering Cancer Center, New York,  New York,  10021,  United States
      NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York,  New York,  10016,  United States

Study chairs or principal investigators

Ira Dunkel,  Study Chair,  Memorial Sloan-Kettering Cancer Center   

Study ID Numbers:  CDR0000065980; MSKCC-97089A3; NCI-G97-1366; NYU-97-7
Record last reviewed:  April 2003
Last Updated:  October 13, 2004
Record first received:  November 1, 1999
ClinicalTrials.gov Identifier:  NCT00003173
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08